IL1B and atherosclerosis: The importance of inflammation in atherosclerosis was confirmed in the CANTOS clinical trial, which showed that anti-inflammatory therapy focused on targeting interleukin 1β (IL-1β) significantly decreased the rate of cardiovascular events [27].